Panacea Biotec Q1 FY27: consolidated PAT down 44% YoY on smaller one-off; core swings to profit
Panacea Biotec's consolidated PAT fell 44.4% YoY to ₹2.20 Cr (from ₹3.96 Cr) even as revenue grew 19.7% YoY to ₹199.57 Cr (₹166.70 Cr) — a decline driven entirely by the size of a non-operating exceptional gain, not by weaker operations. This quarter's exceptional item was ₹2.74 Cr (a recurring deferred-consideration receipt from the 2022 sale of PBPL's domestic pharma brands); the year-ago quarter's ₹11.32 Cr exceptional gain included an ₹8.58 Cr one-time Apotex litigation settlement that did not recur. Stripping exceptional items from both periods, adjusted PAT was a loss of ₹0.54 Cr this quarter versus a loss of ₹7.36 Cr a year ago — a 92.7% narrowing — and consolidated pre-exceptional, pre-tax profit flipped to +₹0.83 Cr from -₹4.76 Cr a year ago, a genuine operating turnaround. Consolidated NPM compressed to 1.08% from 2.30% YoY purely as an arithmetic result of the smaller one-off, not margin erosion in the core business. On a standalone basis — which carries zero exceptional items in either period — PAT swung cleanly from a ₹6.70 Cr loss to a ₹1.39 Cr profit YoY on 20% revenue growth, the more direct read of underlying operating momentum; the standalone-vs-consolidated growth stories diverge materially because of the exceptional-item base effect described above, not because one number is wrong.
Sequentially, consolidated revenue was up 19.7% QoQ (₹166.75 Cr in Q4 FY26) and PAT swung from a ₹1.00 Cr loss to a ₹2.20 Cr profit — a seasonally-unremarkable but real improvement given Q4 FY26 was itself a weak, loss-making quarter. By segment, Vaccines revenue rose to ₹134.67 Cr (₹112.25 Cr YoY) and its PBT swung to a ₹7.47 Cr profit from a ₹4.25 Cr loss a year ago — the clear driver of the print. Formulations revenue also grew, to ₹64.90 Cr (₹54.45 Cr YoY), but its segment PBT reversed to a ₹3.90 Cr loss from a ₹10.81 Cr profit a year ago, partly offsetting the Vaccines gain at the consolidated level.
We found no formal analyst estimates or brokerage previews specific to this quarter, so vsStreet is unknown; management has issued no formal forward guidance on record, so vsGuidance is also unknown. In its notes to the results, management attributes the improved performance to "higher long-term business orders for vaccines from key institutional customers, resulting into higher revenues and profits during the current quarter" — consistent with the Vaccines segment swing seen above — and cites this, plus surplus funds from the 2022 brand-sale proceeds, as the basis for preparing the standalone results on a going-concern basis despite negative standalone retained earnings of ₹216.15 Cr. Separately, the company disclosed a fresh US$8.2 million UNICEF vaccine order on August 5, 2026, which sits alongside this quarter's Vaccines strength but falls in Q2 FY27 and is not reflected in these numbers; a ₹4.06 Cr GST show-cause notice (July 24) and an appeal against a 4th arbitration award (July 16) are both live but immaterial to this quarter's P&L.
